BC Innovations | Oct 30, 2019
Emerging Company Profile

Disc Medicine: Seeking Iron Balance via Hepcidin

Disc debuted Tuesday with a $50 million series A round and a pair of hepcidin modulators aimed at carving a place in hematological disorders, alongside a host of disease-modifying therapies that are much closer to...
BC Innovations | Jul 21, 2011
Distillery Therapeutics

Indication: Hematology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Hematology Anemia Hemochromatosis type 2 juvenile (HFE2); hepcidin A study in rats suggests a soluble form of HFE2 may help treat anemia of chronic disease. In...
BC Week In Review | Nov 22, 2010
Company News

Isis, Xenon deal

Xenon partnered with Isis to discover and develop antisense therapeutics to treat anemia of inflammation. Isis will discover candidates against hemochromatosis type 2 juvenile (HFE2) and hepcidin antimicrobial peptide (HAMP) . Isis will receive an undisclosed...
BC Extra | Nov 17, 2010
Company News

Isis, Xenon in antisense deal

Xenon Pharmaceuticals Inc. (Burnaby, B.C.) partnered with Isis Pharmaceuticals Inc. (NASDAQ:ISIS) to discover and develop antisense therapeutics to treat anemia of inflammation. Isis will discover candidates against hemochromatosis type 2 juvenile (HFE2) and hepcidin antimicrobial...
BC Innovations | Mar 5, 2009
Distillery Therapeutics

Indication: Hematology

This week in therapeutics Indication Target/marker/ pathway Summary Licensing status Publication and contact information Hematology Anemia; hemochromatosis Bone morphogenetic protein 6 (BMP6); hemochromatosis (HFE); hemochromatosis type 2 (juvenile) (HFE2); hepcidin antimicrobial peptide (HAMP) Two separate...
Items per page:
1 - 5 of 5